Approach to Coagulopathies, including DIC & HUS

Ministry of Health, Uganda Seed Global Health, Naguru, Kampala

Dr Clement Okello

06 December 2024

Presentation Objectives

- i. Common aetiologies
- ii. Clinical presentations
- iii. Investigations
- iv. Management in emergency
- v. Common complications
- vi. Emergency disposition plan

Causes of coagulopathies

Congenital

X-linked

Haemophilia A and B

Autosomal

- Von Willebrand disease
- Factor II, V, VII, X, XI and XIII deficiencies
- Combined II, VII, IX and X deficiency
- Combined V and VIII deficiency
- Hypofibrinogenaemia
- Dysfibrinogenaemia

Acquired

Underproduction

Liver failure

Increased consumption

Coagulation activation

Disseminated intravascular coagulation (DIC)

Immune-mediated

Acquired haemophilia and von Willebrand syndrome

Others

Acquired factor X deficiency (in amyloid)
Acquired von Willebrand syndrome in Wilms tumour

Drug-induced

Inhibition of function

Heparins

Lepirudin

Fondaparinux

Rivaroxaban

Dabigatran

Inhibition of synthesis
 Warfarin

Disseminated intravascular coagulation (DIC)


- Acquired syndrome characterized by:
 - Systemic activation of coagulation within the vasculature
 - Leads to microvascular damage, organ dysfunction and haemorrhage
- Triggered by infectious & non-infectious causes
- Infection (sepsis) is the most frequent cause of DIC
- Prevalence of DIC in sepsis varies (18 40%) depending on the target cohorts and diagnostic criteria, but mortality >30% generally

Aetiologies of DIC


Common aetiologies

- Severe systemic infections
- Malignancy
- Trauma
- Obstetrical complications
- Vascular malformations
- Severe immunological reactions
- Heat stroke


Incidence of DIC in critically ill patients




Pathophysiology of DIC




Initiation of coagulation in DIC




Immune mechanisms & propagation of coagulation in DIC



Fibrinolytic modulation of DIC




Pathogenesis of the phenotypes of DIC



Clinical presentations

- Microvascular thrombosis
 - Organ dysfunction,
 - Gangrenes
 - Acute kidney injury
 - Pulmonary & cerebral thrombosis
- Bleeding
 - Petechiae/ecchymoses
 - Necrotizing purpura
 - Vascular access sites
 - Mucosal
 - Organs e.g. adrenals & CNS
- Other features
 - Hypotension
 - Shortness of breath
 - Confusion



Investigations for DIC

• CBC

Peripheral blood smear exam

• PT/aPTT

Fibrinogen

D-dimers

Findings not highly sensitive or specific

To be evaluated in context

 No single lab. test can accurately confirm or eliminate the diagnosis

Scoring systems for DIC

| Item | Score | ISTH overt DIC Range | JAAM DIC Range | ISTH SIC Range |
|----------------------------|-----------|---|---|--------------------------|
| | | | | |
| 2 | < 50 | _ | < 100 | |
| 1 | ≧ 50,<100 | 120 > , 80 ≦ or ≧ 30% decrease within 24 h | ≧ 100,<150 | |
| FDP (D-dimer) | 3 | strong increase | ≧ 25 μg/mL (use convert chart) | - |
| | 2 | moderate increase | _ | _ |
| | 1 | - | ≧ 10, < 25 μg/mL (use convert chart) | - |
| Prothrombin time | 2 | ≧ 6 s | _ | > 1.4 |
| | 1 | ≧ 3 s, < 6 s | ≧ 1.2 (PT ratio) | > 1.2, ≦ 1.4 (PT-INR) |
| Fibrinogen (g/mL) | 1 | < 100 | _ | _ |
| SIRS score | 1 | _ | >3 | _ |
| SOFA score | 2 | _ | _ | ≧2 |
| | 1 | _ | _ | 1 |
| Total score for DIC or SIC | | ≧ 5 | ≧ 4 | ≧ 4 |

Total SOFA score is the sum of 4 items (respiratory SOFA, cardiovascular SOFA, hepatic SOFA, and renal SOFA)

ISTH International Society on Thrombosis and Haemostasis, DIC disseminated intravascular coagulation, JAAM Japanese Society for Acute Medicine, SIC sepsis-induced coagulopathy, SIRS systemic inflammatory response syndrome, SOFA Sequential Organ Failure Assessment

DIC vs other thrombotic microangiopathies

- Other TMAs generally present with thrombocytopenia and normal coagulation studies unlike DIC.
- In some cases, other TMAs are caused by clearly defined endothelial defects:
 - TTP is caused by deficiency of the ADAMTS13 protease,
 - Complement-mediated HUS
- Both DIC and other TMAs can produce microangiopathic hemolytic anemia (MAHA)

Discussion of Management...